EIDD-2801 Molnupiravir Powder CAS 2349386-89-4 For Feline Infectious Peritonitis

EIDD-2801, also known as Molnupiravir, is an antiviral drug developed for the treatment of viral infections, particularly those caused by RNA viruses.

EIDD-2801 is a small molecule antiviral drug with a chemical structure that enables it to interfere with the replication process of RNA viruses. As a prodrug, it is metabolized in the body into its active form to exert its antiviral effects.

The primary mechanism of action involves inhibiting viral replication by inducing lethal mutations in the viral genetic material. When metabolized into its active form, EIDD-2801 mimics RNA building blocks, introducing errors into viral RNA sequences during replication. This results in nonviable or less infectious viral progeny, effectively disrupting viral spread.

EIDD-2801 demonstrates broad-spectrum activity against various RNA viruses including influenza viruses, coronaviruses (such as SARS-CoV-2), and respiratory syncytial virus (RSV), making it a promising treatment for multiple viral infections.

Molnupiravir gained significant attention during the COVID-19 pandemic as a potential oral antiviral treatment for SARS-CoV-2. Clinical trials demonstrate its ability to reduce viral shedding duration and symptoms when administered early in infection, potentially limiting viral spread and illness severity.

• 1~25kgs packaging: Aluminium bag inside, Carton box outside
• 25kgs packaging: Plastic bag inside, Fiber drum outside